Brief reportTransvenous atrial septal defect occlusion by the buttoned device
References (6)
- et al.
Secundum atrial septal defect: nonoperative closure during cardiac catheterization
JAMA
(1976) Transcatheter treatment of congenital heart disease
Circulation
(1983)- et al.
Transcatheter umbrella closure of congenital heart defects
Circulation
(1987)
Cited by (133)
Cardiac Tamponade Due to Very Late Perforation of Left Atrium by Atrial Septal Defect Occluder
2021, JACC: Cardiovascular InterventionsInterventional cardiac catheterization in congenital heart disease
2017, Presse MedicalePercutaneous closure of secundum atrial septal defects
2012, Progress in Pediatric CardiologyCitation Excerpt :However, neither device was able to receive FDA approval and with the closure of NMT medical in 2011, the CardioSEAL and STARFlex devices are no longer manufactured. In 1990, Sideris reported the first clinical use of the so-called “buttoned” device which consisted of a square sheet of polyurethane foam supported by an x-shaped wire frame (the left atrial “occluder”) and a separate metal bar with a rubber piece sewn to its center(the right atrial “counter occluder”) [9] (Fig. 8). The rubber piece acts as the “button hole”.
Treatment of isolated secundum atrial septal defects: Impact of age and defect morphology in 1,013 consecutive patients
2008, American Heart JournalCitation Excerpt :Percutaneous closure was possible in 67 patients (81%), whereas in the remaining cases (7 multi-fenestrated ASDs, 1 with multiple ASD, and 8 with central defects), procedural failure was mainly related to inadequate stability of the device. Transcatheter technique for ASD occlusion has been developed in the recent years and is now considered valuable alternative to surgical treatment.2-13 However, not all cases of ASD II are suitable for percutaneous treatment.
Human Genetics of Congenital Heart Disease
2007, Advances in Developmental BiologyCitation Excerpt :The pioneering work of King and Mills (1974, 1976) resulted in the development of a double‐umbrella device and established the feasibility of occluding atrial septal defects with percutaneous devices. Many other devices were subsequently developed, including the Rashkind single‐disc device, Locke USCI “clamshell” device, “buttoned” device, ASDOS device, Manodisk device, Das Angel Wings, Amplatzer device, and the Cardioseal device (Rashkind, 1985; Lock et al., 1987; Babic et al., 1990; Rome et al., 1990; Sideris et al., 1990; Sievert et al., 1990; Rao et al., 1991, 1992; Ruiz et al., 1992; Boutin et al., 1993; Das et al., 1993; O'Laughlin et al., 1993; Pavcnik et al., 1993; Perry et al., 1993; Hausdorf et al., 1995; Zamora et al., 1995; Sharafudin et al., 1996; Sievert et al., 1997; Pedra et al., 2003; Schrader, 2003; Butera et al., 2004; Kay et al., 2004; Purcell et al., 2004; Celiker et al., 2005). These are now standard therapies.